We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current POXEL market cap is 17.75M. The company's latest EPS is EUR -0.7532 and P/E is -0.50.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 30.93M | 6.81M | 13.4M | 674k | 1.98M |
| Operating Income | -24.67M | -29.82M | -22.46M | -21.89M | -28.76M |
| Net Income | -25.74M | -31.83M | -23.76M | -31.4M | -35.09M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 72.3M | 65.08M | 54.89M | 34.71M | 4.82M |
| Total Liabilities | 33.16M | 38.01M | 46.68M | 52.96M | 53.9M |
| Total Equity | 39.14M | 27.07M | 8.21M | -18.24M | -49.08M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -25.69M | -25.75M | -16.89M | -21.81M | -13.98M |
| Investing | 352k | 52k | -43k | N/A | 42k |
| Financing | -4.21M | 28.71M | 9.02M | 2.59M | 3.23M |
| Market Cap | 17.75M |
| Price to Earnings Ratio | -0.50 |
| Price to Sales Ratio | 8.94 |
| Price to Cash Ratio | 7.55 |
| Price to Book Ratio | -0.36 |
| Dividend Yield | - |
| Shares Outstanding | 46.59M |
| Average Volume (1 week) | 1.52M |
| Average Volume (1 Month) | 1.39M |
| 52 Week Change | -38.65% |
| 52 Week High | 0.896 |
| 52 Week Low | 0.115 |
| Spread (Intraday) | 0.01 (2.56%) |
| Company Name | Poxel |
| Address |
259/261 avenue jean jaures - immeuble le sunway lyon, rhone 69007 |
| Website | https://www.poxelpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
